Falk Gastro-Kolleg Leber und Gallenwege Fragen zur ...

13 Fountain FF, Tolley E, Chrisman CR, Self TH.
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection:
a 7-year evaluation from a public health tuberculosis clinic.
Chest 2005; 128: 116–123.
Literatur
14 Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA,
Villar M, Rodrigo L, Romero-Gomez M, Planas R, Barriocanal A, Costa J, Guarner C,
Blanco S, Navarro JM, Pons F, Castiella A, Avila S; Spanish Group for the Study of
Drug-Induced Liver Disease (Grupo de Estudio para las Hepatopatías Asociadas
a Medicamentos (GEHAM)).
Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity:
a prospective series from Spain.
Hepatology 2006; 44: 850–856.
15 Lucena MI, Andrade RJ, Kaplowitz N, García-Cortes M, Fernández MC,
Romero-Gomez M, Bruguera M, Hallal H, Robles-Diaz M, Rodriguez-González JF,
Navarro JM, Salmeron J, Martinez-Odriozola P, Pérez-Alvarez R, Borraz Y, Hidalgo R;
Spanish Group for the Study of Drug-Induced Liver Disease.
Phenotypic characterization of idiosyncratic drug-induced liver injury:
the influence of age and sex.
Hepatology 2009; 49: 2001–2009.
16 Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P.
Liver transplantation for acute liver failure from drug induced liver injury in the
United States.
Liver Transpl 2004; 10: 1018–1023.
17 Hasler JA.
Pharmacogenetics of cytochromes P450.
Mol Aspects Med 1999; 20: 12–24, 25–137.
18 Yun CH, Okerholm RA, Guengerich FP.
Oxidation of the antihistaminic drug terfenadine in human liver microsomes.
Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation.
Drug Metab Dispos 1993; 21: 403–409.
19 Steele MA, Burk RF, DesPrez RM.
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
Chest 1991; 99: 465–471.
20 Pessayre D, Bentata M, Degott C, Nouel O, Miguet JP, Rueff B, Benhamou JP.
Isoniazid-rifampin fulminant hepatitis. A possible consequence of the
enhancement of isoniazid hepatotoxicity by enzyme induction.
Gastroenterology 1977; 72: 284–289.
21 Lammert C, Bjornsson E, Niklasson A, Chalasani N.
Oral medications with significant hepatic metabolism at higher risk for hepatic
adverse events.
Hepatology 2010; 51: 615–620.
22 Schmidt LE, Dalhoff K, Poulsen HE.
Acute versus chronic alcohol consumption in acetaminophen-induced
hepatotoxicity.
Hepatology 2002; 35: 876–882.
23 Russo MW, Watkins PB.
Are patients with elevated liver tests at increased risk of drug-induced liver injury?
Gastroenterology 2004; 126: 1477–1480.
47